

Otto C Boerman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/876591/publications.pdf>

Version: 2024-02-01

394
papers

19,710
citations

13332

70
h-index

22488

117
g-index

396
all docs

396
docs citations

396
times ranked

21448
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells. <i>Molecular Pharmaceutics</i> , 2022, 19, 3511-3520.	2.3	6
2	Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin. <i>Nature Communications</i> , 2022, 13, 2621.	5.8	14
3	Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models. <i>Physics and Imaging in Radiation Oncology</i> , 2021, 19, 145-150.	1.2	2
4	Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. <i>MABs</i> , 2021, 13, 1913791.	2.6	53
5	A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using ⁶⁸ Ga-RGD PET/CT. <i>Journal of Nuclear Medicine</i> , 2020, 61, 270-275.	2.8	7
6	Additional information on ⁶⁸ Zr-DFO, ⁶⁸ Zr-DFO* and ⁶⁸ Zr-DFOcyclo* for ⁸⁹ Zr-immunoPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 505-506.	3.3	2
7	Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with ¹¹¹ In-girentuximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1864-1870.	3.3	6
8	Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [¹³ C]pyruvate MRS and [¹⁸ F]FDG-PET. <i>NMR in Biomedicine</i> , 2020, 33, e4362.	1.6	5
9	Targeting of radioactive platinum-bisphosphonate anticancer drugs to bone of high metabolic activity. <i>Scientific Reports</i> , 2020, 10, 5889.	1.6	15
10	Ex Vivo Assessment of Tumor-Targeting Fluorescent Tracers for Image-Guided Surgery. <i>Cancers</i> , 2020, 12, 987.	1.7	8
11	Measuring the Pancreatic β Cell Mass in Vivo with Exendin SPECT during Hyperglycemia and Severe Insulinitis. <i>Molecular Pharmaceutics</i> , 2019, 16, 4024-4030.	2.3	14
12	Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors. <i>Theranostics</i> , 2019, 9, 2924-2938.	4.6	41
13	PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery. <i>Theranostics</i> , 2019, 9, 6824-6839.	4.6	56
14	Lesion detection by [⁸⁹ Zr]Zr-DFO-girentuximab and [¹⁸ F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1931-1939.	3.3	53
15	Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for ⁸⁹ Zr-immunoPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1966-1977.	3.3	54
16	Monitoring ¹¹¹ In-labelled polyisocyanopeptide (PIC) hydrogel wound dressings in full-thickness wounds. <i>Biomaterials Science</i> , 2019, 7, 3041-3050.	2.6	22
17	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. <i>Scientific Reports</i> , 2019, 9, 18898.	1.6	22
18	Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models. <i>Molecular Pharmaceutics</i> , 2019, 16, 701-708.	2.3	20

#	ARTICLE	IF	CITATIONS
19	PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 150-161.	1.6	29
20	In Vitro and In Vivo Characterization of an ¹⁸ F-AIF-Labeled PSMA Ligand for Imaging of PSMA-Expressing Xenografts. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1017-1022.	2.8	19
21	A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer. <i>EJNMMI Research</i> , 2019, 9, 86.	1.1	4
22	Carcinoembryonic antigen-targeted photodynamic therapy in colorectal cancer models. <i>EJNMMI Research</i> , 2019, 9, 108.	1.1	7
23	The kinetics and mechanism of bone morphogenetic protein 2 release from calcium phosphate-based implant coatings. <i>Journal of Biomedical Materials Research - Part A</i> , 2018, 106, 2363-2371.	2.1	28
24	In Vivo Characterization of 4 ⁶⁸ Ga-Labeled Multimeric RGD Peptides to Image $\alpha_v\beta_3$ Integrin Expression in 2 Human Tumor Xenograft Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1296-1301.	2.8	23
25	Characterization of ¹¹¹ In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors. <i>Scientific Reports</i> , 2018, 8, 2948.	1.6	9
26	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. <i>Rheumatology</i> , 2018, 57, 737-747.	0.9	22
27	Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and <i>In Vivo</i> Beta Cell Imaging. <i>Molecular Pharmaceutics</i> , 2018, 15, 486-494.	2.3	8
28	Positron Emission Tomography/Computed Tomography with ⁸⁹ Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. <i>European Urology</i> , 2018, 74, 257-260.	0.9	65
29	Intraoperative Imaging Techniques to Support Complete Tumor Resection in Partial Nephrectomy. <i>European Urology Focus</i> , 2018, 4, 960-968.	1.6	58
30	Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 780-786.	2.8	14
31	Characterization of Site-Specifically Conjugated Monomethyl Auristatin E and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 494-501.	2.8	12
32	Validation of ¹¹¹ In-Exendin SPECT for the Determination of the β_2 -Cell Mass in BioBreeding Diabetes-Prone Rats. <i>Diabetes</i> , 2018, 67, 2012-2018.	0.3	13
33	Targeting CD44v6 for fluorescence-guided surgery in head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2018, 8, 10467.	1.6	24
34	Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. <i>Theranostics</i> , 2018, 8, 2161-2170.	4.6	97
35	Bisphosphonate-Functionalized Imaging Agents, Anti-Tumor Agents and Nanocarriers for Treatment of Bone Cancer. <i>Advanced Healthcare Materials</i> , 2017, 6, 1601119.	3.9	39
36	α - Versus β -Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. <i>Journal of Nuclear Medicine</i> , 2017, 58, 926-933.	2.8	34

#	ARTICLE	IF	CITATIONS
37	Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. <i>Journal of Nuclear Medicine</i> , 2017, 58, 706-710.	2.8	37
38	Design of Radioiodinated Pharmaceuticals: Structural Features Affecting Metabolic Stability towards in Vivo Deiodination. <i>European Journal of Organic Chemistry</i> , 2017, 2017, 3387-3414.	1.2	52
39	²¹³ Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 67-73.	0.7	47
40	Quantitative and longitudinal imaging of intramuscular transplanted islets of Langerhans with SPECT using [¹²³ I]IBZM. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 604-608.	2.2	3
41	Response Monitoring with [18F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. <i>Molecular Imaging and Biology</i> , 2017, 19, 540-549.	1.3	6
42	Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging. <i>Molecular Pharmaceutics</i> , 2017, 14, 3457-3463.	2.3	34
43	⁸⁹ Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art ⁸⁹ Zr Radiochemistry. <i>Bioconjugate Chemistry</i> , 2017, 28, 2211-2223.	1.8	146
44	Non-invasive in vivo determination of viable islet graft volume by ¹¹¹ In-exendin-3. <i>Scientific Reports</i> , 2017, 7, 7232.	1.6	20
45	Preclinical validation of ¹¹¹ In-girentuximab-F(ab ²) ₂ as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts. <i>Radiotherapy and Oncology</i> , 2017, 124, 521-525.	0.3	13
46	Perfluorocarbon/Gold Loading for Noninvasive in Vivo Assessment of Bone Fillers Using ¹⁹ F Magnetic Resonance Imaging and Computed Tomography. <i>ACS Applied Materials & Interfaces</i> , 2017, 9, 22149-22159.	4.0	15
47	Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan. <i>Scientific Reports</i> , 2017, 7, 1751.	1.6	1
48	Digitalis-like Compounds Facilitate Non-Medullary Thyroid Cancer Redifferentiation through Intracellular Ca ²⁺ , FOS, and Autophagy-Dependent Pathways. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 169-181.	1.9	19
49	In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow. <i>Journal of Nuclear Medicine</i> , 2017, 58, 214-220.	2.8	17
50	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Anti- ⁶⁴ Fibroblast Activation Protein Antibody. <i>Journal of Nuclear Medicine</i> , 2017, 58, 151-155.	2.8	32
51	Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents. <i>Theranostics</i> , 2017, 7, 1-8.	4.6	22
52	Full preclinical validation of the ¹²³ I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. <i>Oncotarget</i> , 2017, 8, 10919-10930.	0.8	17
53	SPECT vs. PET monitoring of bone defect healing and biomaterial performance <i>in vivo</i> . <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2016, 10, 843-854.	1.3	16
54	SPECT of Transplanted Islets of Langerhans by Dopamine 2 Receptor Targeting in a Rat Model. <i>Molecular Pharmaceutics</i> , 2016, 13, 85-91.	2.3	9

#	ARTICLE	IF	CITATIONS
55	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. <i>Theranostics</i> , 2016, 6, 849-861.	4.6	102
56	Radionuclide imaging of liposomal drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1231-1242.	2.4	41
57	Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An <i>Ex Vivo</i> Kidney Perfusion Study. <i>Clinical Cancer Research</i> , 2016, 22, 4634-4642.	3.2	38
58	PET of EGFR with ⁶⁴ Cu- <i>cetuximab</i> -(<i>ab</i>) ₂ in mice with head and neck squamous cell carcinoma xenografts. <i>Contrast Media and Molecular Imaging</i> , 2016, 11, 65-70.	0.4	26
59	CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 2715-2725.	0.4	43
60	Improved Quantification of the Beta Cell Mass after Pancreas Visualization with ^{99m} Tc-demobesin-4 and Beta Cell Imaging with ¹¹¹ In-exendin-3 in Rodents. <i>Molecular Pharmaceutics</i> , 2016, 13, 3478-3483.	2.3	8
61	The effect of purification of Ga-68-labeled exendin on in vivo distribution. <i>EJNMMI Research</i> , 2016, 6, 65.	1.1	18
62	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin α _v β ₃ . <i>Journal of Nuclear Medicine</i> , 2016, 57, 467-472.	2.8	38
63	Strain Differences Determine the Suitability of Animal Models for Noninvasive In Vivo Beta Cell Mass Determination with Radiolabeled Exendin. <i>Molecular Imaging and Biology</i> , 2016, 18, 705-714.	1.3	20
64	Phase 2 Study of Lutetium 177- ¹⁷⁷ Lu-Labeled Anti- ¹⁷⁷ Lu-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 767-770.	0.9	57
65	^{99m} Tc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease. <i>Journal of Nuclear Medicine</i> , 2016, 57, 398-403.	2.8	25
66	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 327-339.	2.0	50
67	Noninvasive Imaging of Islet Transplants with ¹¹¹ In-Exendin-3 SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2016, 57, 799-804.	2.8	11
68	Graft revascularization is essential for non-invasive monitoring of transplanted islets with radiolabeled exendin. <i>Scientific Reports</i> , 2015, 5, 15521.	1.6	13
69	Central delivery of iodine-125-labeled cetuximab, etanercept and anakinra after perispinal injection in rats: possible implications for treating Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 70.	3.0	14
70	Therapy response monitoring of the early effects of a new BRAF inhibitor on melanoma xenograft in mice: evaluation of ¹⁸ F-FDG-PET and ¹⁸ F-FLT-PET. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 203-210.	0.4	7
71	PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. <i>Theranostics</i> , 2015, 5, 1388-1401.	4.6	186
72	Upregulation of IGF-1R Expression during Neoadjuvant Therapy Predicts Poor Outcome in Breast Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0117745.	1.1	32

#	ARTICLE	IF	CITATIONS
73	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00015.	0.7	37
74	A Novel ¹¹¹ In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1094-1099.	2.8	102
75	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015, 75, 2928-2936.	0.4	193
76	Comparison of three remote radiolabelling methods for long-circulating liposomes. <i>Journal of Controlled Release</i> , 2015, 220, 239-244.	4.8	23
77	Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. <i>Journal of Urology</i> , 2015, 194, 532-538.	0.2	21
78	¹¹¹ In-Cetuximab-F(ab) ₂ SPECT and ¹⁸ F-FDG PET for Prediction and Response Monitoring of Combined-Modality Treatment of Human Head and Neck Carcinomas in a Mouse Model. <i>Journal of Nuclear Medicine</i> , 2015, 56, 287-292.	2.8	20
79	¹¹¹ In-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1430-1438.	3.3	22
80	Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC. <i>Neoplasia</i> , 2015, 17, 215-224.	2.3	14
81	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015, 56, 778-783.	2.8	84
82	[¹⁸ F]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. <i>Journal of Controlled Release</i> , 2015, 209, 20-26.	4.8	23
83	Pretargeted ImmunoPET of Prostate Cancer with an Anti-TROP-2 x Anti-HSG Bispecific Antibody in Mice with PC3 Xenografts. <i>Molecular Imaging and Biology</i> , 2015, 17, 94-101.	1.3	17
84	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. <i>EJNMMI Physics</i> , 2015, 2, 5.	1.3	10
85	PET Imaging in Head and Neck Cancer Patients to Monitor Treatment Response: A Future Role for EGFR-Targeted Imaging. <i>Clinical Cancer Research</i> , 2015, 21, 3602-3609.	3.2	25
86	¹¹¹ In-exendin Uptake in the Pancreas Correlates With the β -Cell Mass and Not With the α -Cell Mass. <i>Diabetes</i> , 2015, 64, 1324-1328.	0.3	31
87	Epidermal growth factor receptor imaging in human head and neck cancer xenografts. <i>Acta Oncologica</i> , 2015, 54, 1263-1267.	0.8	7
88	Targeting human prostate cancer with ¹¹¹ In-labeled D2B IgG, F(ab) ₂ and Fab fragments in nude mice with PSMA-expressing xenografts. <i>Contrast Media and Molecular Imaging</i> , 2015, 10, 28-36.	0.4	33
89	Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery. <i>Current Drug Targets</i> , 2015, 16, 625-633.	1.0	7
90	Carbonic Anhydrase IX and Monoclonal Antibody G250: Relevance as a Clinical and Biologic Target in Renal Cell Carcinoma. , 2015, , 263-284.		0

#	ARTICLE	IF	CITATIONS
91	Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, e14014-e14014.	0.8	0
92	Cathepsin B Mediated Lysosomal Degradation in Macrophages Controls the Pharmacokinetics of the Therapeutic Protein Asparaginase. Blood, 2015, 126, 3768-3768.	0.6	0
93	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. Molecular Imaging, 2015, 14, 348-55.	0.7	14
94	Optimizing Lutetium 177â€“Antiâ€“Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model. Molecular Imaging, 2014, 13, 7290.2014.00008.	0.7	11
95	Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount. EJNMMI Research, 2014, 4, 47.	1.1	19
96	Early Response Monitoring with ¹⁸ F-FDG PET and Cetuximab-F(abâ€²) ₂ -SPECT After Radiotherapy of Human Head and Neck Squamous Cell Carcinomas in a Mouse Model. Journal of Nuclear Medicine, 2014, 55, 1665-1670.	2.8	11
97	Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients. BioMed Research International, 2014, 2014, 1-13.	0.9	103
98	mTOR Inhibition Promotes TTF1-Dependent Redifferentiation and Restores Iodine Uptake in Thyroid Carcinoma Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1368-E1375.	1.8	32
99	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. Molecular Pharmaceutics, 2014, 11, 4249-4257.	2.3	8
100	Al ¹⁸ F labeling of peptides and proteins. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 219-223.	0.5	44
101	Preclinical Comparison of Al ¹⁸ F- and ⁶⁸ Ga-Labeled Gastrin-Releasing Peptide Receptor Antagonists for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 2014, 55, 2050-2056.	2.8	46
102	Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. International Journal of Cancer, 2014, 135, 2770-2782.	2.3	20
103	Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer. Cancer Research, 2014, 74, 6216-6223.	0.4	25
104	Theranostic applications of antibodies in oncology. Molecular Oncology, 2014, 8, 799-812.	2.1	53
105	Dynamics of IGF-1R Expression During Endocrine Breast Cancer Treatment. Molecular Imaging and Biology, 2014, 16, 529-37.	1.3	4
106	Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹ In-labelled exendin. Diabetologia, 2014, 57, 950-959.	2.9	129
107	Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 266-276.	3.3	31
108	Monitoring the biological effect of BMP-2 release on bone healing by PET/CT. Journal of Controlled Release, 2014, 183, 138-144.	4.8	16

#	ARTICLE	IF	CITATIONS
109	Specific targeting of tumor cells by lyophilisomes functionalized with antibodies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 87, 80-89.	2.0	10
110	Preclinical Imaging in Bone Tissue Engineering. <i>Tissue Engineering - Part B: Reviews</i> , 2014, 20, 578-595.	2.5	25
111	Development of injectable organic/inorganic colloidal composite gels made of self-assembling gelatin nanospheres and calcium phosphate nanocrystals. <i>Acta Biomaterialia</i> , 2014, 10, 508-519.	4.1	63
112	Can ¹¹¹ In-RGD ₂ Monitor Response to Therapy in Head and Neck Tumor Xenografts?. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1849-1855.	2.8	16
113	Tyrosine Kinase Inhibitor Sorafenib Decreases ¹¹¹ In-Girentuximab Uptake in Patients with Clear Cell Renal Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2014, 55, 242-247.	2.8	31
114	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2—Anti-HSG Bispecific Antibody and a ¹⁷⁷ Lu-Labeled Peptide. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2014, 29, 323-329.	0.7	28
115	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 175-185.	2.4	7
116	SPECT- and Fluorescence Image—Guided Surgery Using a Dual-Labeled Carcinoembryonic Antigen—Targeting Antibody. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1519-1524.	2.8	35
117	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1593-602.	3.3	33
118	Optical Imaging of Renal Cell Carcinoma with Anti—Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1035-1040.	2.8	23
119	Imaging Integrin $\alpha_5\beta_1$ on Blood Vessels with ¹¹¹ In-RGD ₂ in Head and Neck Tumor Xenografts. <i>Journal of Nuclear Medicine</i> , 2014, 55, 281-286.	2.8	24
120	Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. <i>Journal of Nuclear Medicine</i> , 2014, 55, 995-1001.	2.8	78
121	Preclinical Studies of SPECT and PET Tracers for NET. <i>PET Clinics</i> , 2014, 9, 63-69.	1.5	1
122	Pretargeted Imaging and Radioimmunotherapy of Cancer Using Antibodies and Bioorthogonal Chemistry. <i>Frontiers in Medicine</i> , 2014, 1, 44.	1.2	53
123	The Therapeutic Protein Asparaginase Is Efficiently Cleared By Bone Marrow and Spleen Resident Macrophages. <i>Blood</i> , 2014, 124, 3630-3630.	0.6	1
124	The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. <i>Oncotarget</i> , 2014, 5, 12753-12768.	0.8	46
125	Radiolabeled Imaging Probes Targeting Angiogenesis for Personalized Medicine. <i>Current Pharmaceutical Design</i> , 2014, 20, 2293-2307.	0.9	3
126	Effects of attenuation map accuracy on attenuation-corrected micro-SPECT images. <i>EJNMMI Research</i> , 2013, 3, 7.	1.1	4

#	ARTICLE	IF	CITATIONS
127	In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cellular and Molecular Life Sciences, 2013, 70, 2237-2257.	2.4	21
128	Tubular reabsorption and local production of urine hepcidin-25. BMC Nephrology, 2013, 14, 70.	0.8	27
129	Phase 1 Radioimmunotherapy Study with Lutetium 177 ^{â€} labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. European Urology, 2013, 64, 478-485.	0.9	71
130	Indium-111 ^{â€} labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. European Urology, 2013, 63, 1101-1106.	0.9	69
131	Imaging integrin alpha ^{â€} v ^{â€} beta ^{â€} 3 expression in tumors with an ¹⁸ F ^{â€} labeled dimeric RGD peptide. Contrast Media and Molecular Imaging, 2013, 8, 238-245.	0.4	36
132	111In-cetuximab-F(ab ^{â€}) ₂ SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts. Radiotherapy and Oncology, 2013, 108, 484-488.	0.3	17
133	Reply to John Samuel Banerji's Letter to the Editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111 ^{â€} Labeled Girentuximab ImmunoSPECT as a Diagnostic Tool in Clear Cell Renal Cell Carcinoma. Eur Urol 2013;63:1101 ^{â€} 6. European Urology, 2013, 64, e83.	0.9	0
134	The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab ^{â€}) ₂ -R1507 fragments in Ewing sarcomas. European Journal of Cancer, 2013, 49, 2851-2858.	1.3	10
135	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. Cancer Research, 2013, 73, 1063-1075.	0.4	295
136	Combined delivery of BMP-2 and bFGF from nanostructured colloidal gelatin gels and its effect on bone regeneration in vivo. Journal of Controlled Release, 2013, 166, 172-181.	4.8	156
137	<i>In Vivo</i> and <i>In Vitro</i> Studies on Renal Uptake of Radiolabeled Affibody Molecules for Imaging of HER2 Expression in Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 187-195.	0.7	30
138	1-Step Versus 2-Step Immobilization of Alkaline Phosphatase and Bone Morphogenetic Protein-2 onto Implant Surfaces Using Polydopamine. Tissue Engineering - Part C: Methods, 2013, 19, 610-619.	1.1	30
139	Expression and clinical relevance of MET and ALK in Ewing sarcomas. International Journal of Cancer, 2013, 133, 427-436.	2.3	48
140	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1377-1383.	3.3	41
141	Incorporation of stromal cell-derived factor-1 ^{â€} in PCL/gelatin electrospun membranes for guided bone regeneration. Biomaterials, 2013, 34, 735-745.	5.7	155
142	Dual Contrast Agent for Computed Tomography and Magnetic Resonance Hard Tissue Imaging. Tissue Engineering - Part C: Methods, 2013, 19, 405-416.	1.1	20
143	Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy, 2013, 5, 489-495.	1.0	14
144	Application of Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2013, 14, 11402-11423.	1.8	62

#	ARTICLE	IF	CITATIONS
145	Imaging of Epidermal Growth Factor Receptor Expression in Head and Neck Cancer with SPECT/CT and ¹¹¹ In-Labeled Cetuximab-F(ab ²) ₂ . Journal of Nuclear Medicine, 2013, 54, 2118-2124.	2.8	42
146	Bevacizumab reduces tumor targeting of anti-epidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. International Journal of Cancer, 2013, 133, 307-314.	2.3	49
147	The biological performance of injectable calcium phosphate/PLGA cement in osteoporotic rats. Biomedical Materials (Bristol), 2013, 8, 035012.	1.7	11
148	ImmunoPET Imaging of Renal Cell Carcinoma with ¹²⁴ I- and ⁸⁹ Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 510-515.	0.7	46
149	¹⁸ F: A New Standard for Radiofluorination. Journal of Nuclear Medicine, 2013, 54, 1170.1-1170.	2.8	6
150	Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2R ^{gnull} Mice. PLoS ONE, 2013, 8, e64384.	1.1	71
151	Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with ¹⁸ F-Labeled Affibody Molecule ZHER2:2395 in a Mouse Model for Ovarian Cancer. Journal of Nuclear Medicine, 2012, 53, 146-153.	2.8	66
152	PS2 - 7. Non-invasive determination of the beta cell mass by SPECT with ¹¹¹ In-exendin in a rat model for spontaneous type 1 diabetes. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 104-104.	0.0	0
153	Dosimetric Analysis of ¹⁷⁷ Lu-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on ¹¹¹ In-cG250 Imaging. Journal of Nuclear Medicine, 2012, 53, 82-89.	2.8	45
154	Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. Journal of Nuclear Medicine, 2012, 53, 1926-1932.	2.8	12
155	In Vitro and In Vivo Characterization of Three ⁶⁸ Ga- and ¹¹¹ In-Labeled Peptides for Cholecystokinin Receptor Imaging. Molecular Imaging, 2012, 11, 7290.2012.00001.	0.7	7
156	¹⁸ F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging for the Detection of Experimental Colorectal Liver Metastases. Molecular Imaging, 2012, 11, 7290.2011.00035.	0.7	2
157	A New Tri-Fab Bispecific Antibody for Pretargeting Trop-2-Expressing Epithelial Cancers. Journal of Nuclear Medicine, 2012, 53, 1625-1632.	2.8	35
158	PET of Tumors Expressing Gastrin-Releasing Peptide Receptor with an ¹⁸ F-Labeled Bombesin Analog. Journal of Nuclear Medicine, 2012, 53, 947-952.	2.8	65
159	Optimization of IGF-1R SPECT/CT Imaging Using ¹¹¹ In-Labeled F(ab ²) ₂ and Fab Fragments of the Monoclonal Antibody R1507. Molecular Pharmaceutics, 2012, 9, 2314-2321.	2.3	35
160	Surface modifications by gas plasma control osteogenic differentiation of MC3T3-E1 cells. Acta Biomaterialia, 2012, 8, 2969-2977.	4.1	36
161	Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. Cardiovascular Diabetology, 2012, 11, 124.	2.7	24
162	Differential loading methods for BMP-2 within injectable calcium phosphate cement. Journal of Controlled Release, 2012, 164, 283-290.	4.8	50

#	ARTICLE	IF	CITATIONS
163	Comparison of micro- vs. nanostructured colloidal gelatin gels for sustained delivery of osteogenic proteins: Bone morphogenetic protein-2 and alkaline phosphatase. <i>Biomaterials</i> , 2012, 33, 8695-8703.	5.7	152
164	Prospects in radionuclide imaging of prostate cancer. <i>Prostate</i> , 2012, 72, 1262-1272.	1.2	27
165	Radiolabelled GLP-1 analogues for <i>in vivo</i> targeting of insulinomas. <i>Contrast Media and Molecular Imaging</i> , 2012, 7, 160-166.	0.4	44
166	Radiolabelled peptides for oncological diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 78-92.	3.3	71
167	Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with ¹¹¹ In in HEPES and MES buffer. <i>EJNMMI Research</i> , 2012, 2, 4.	1.1	44
168	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. <i>EJNMMI Research</i> , 2012, 2, 5.	1.1	22
169	Optimized labeling of NOTA-conjugated octreotide with F-18. <i>Tumor Biology</i> , 2012, 33, 427-434.	0.8	72
170	¹⁸ F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 461-462.	3.3	8
171	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13111-e13111.	0.8	1
172	Atorvastatin does not Affect Ischaemia-Induced Phosphatidylserine Exposition in Humans in-vivo. <i>Journal of Atherosclerosis and Thrombosis</i> , 2012, 19, 285-291.	0.9	3
173	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3035-3035.	0.8	0
174	Preclinical Evaluation of ⁶⁸ Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors. <i>Molecular Imaging</i> , 2011, 10, 7290.2010.00032.	0.7	19
175	Adjuvant Radioimmunotherapy Improves Survival of Rats After Resection of Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2011, 253, 336-341.	2.1	10
176	Angiotensin II Type 1 Receptor Blockade Does Not Enhance Apoptotic Cell Death During Ischemia and Reperfusion in Humans In Vivo. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 57, 702-706.	0.8	4
177	Image quality phantom and parameters for high spatial resolution small-animal SPECT. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2011, 654, 539-545.	0.7	9
178	Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients. <i>Clinical Cancer Research</i> , 2011, 17, 5725-5735.	3.2	158
179	Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. <i>Amino Acids</i> , 2011, 41, 1049-1058.	1.2	63
180	PET imaging of $\alpha_v\beta_3$ integrin expression in tumours with ⁶⁸ Ga-labelled mono-, di- and tetrameric RGD peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 128-137.	3.3	107

#	ARTICLE	IF	CITATIONS
181	Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 623-632.	3.3	108
182	Comparative biodistribution of 12 ¹¹¹ In-labelled gastrin/CCK2 receptor-targeting peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1410-1416.	3.3	88
183	Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1407-1409.	3.3	2
184	Effect of nanotubes and apatite on growth factor release from PLLA scaffolds. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2011, 5, 476-482.	1.3	8
185	Localization, mechanism and reduction of renal retention of technetium- ^{99m} labeled epidermal growth factor receptor-specific nanobody in mice. <i>Contrast Media and Molecular Imaging</i> , 2011, 6, 85-92.	0.4	108
186	Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. <i>International Journal of Cancer</i> , 2011, 129, 870-878.	2.3	53
187	Spacer Effects on in vivo Properties of DOTA-Conjugated Dimeric [Tyr ³]Octreotate Peptides Synthesized by a ¹ Cu-Click and ² Sulfo-Click Ligation Method. <i>ChemBioChem</i> , 2011, 12, 750-760.		17
188	Characterization and optimization of image quality as a function of reconstruction algorithms and parameter settings in a Siemens Inveon small-animal PET scanner using the NEMA NU 4-2008 standards. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2011, 629, 357-367.	0.7	16
189	Imaging of Prostate Cancer with Immuno-PET and Immuno-SPECT Using a Radiolabeled Anti-EGP-1 Monoclonal Antibody. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1601-1607.	2.8	29
190	PL - 92. Non-invasive determination of the beta cell mass in rats by SPECT with In-111-DTPA-Exendin-3. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011, 9, 154-155.	0.0	0
191	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507. <i>Clinical Cancer Research</i> , 2011, 17, 7693-7703.	3.2	39
192	Using the NEMA NU 4 PET Image Quality Phantom in Multipinhole Small-Animal SPECT. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1646-1653.	2.8	30
193	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3-fluoro-3-deoxy-thymidine ([¹⁸ F]FLT) PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18396-18399.	3.3	65
194	Immuno-PET of Cancer: A Revival of Antibody Imaging. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1171-1172.	2.8	44
195	Diannexin Protects against Renal Ischemia Reperfusion Injury and Targets Phosphatidylserines in Ischemic Tissue. <i>PLoS ONE</i> , 2011, 6, e24276.	1.1	35
196	Preclinical evaluation of ⁶⁸ Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. <i>Molecular Imaging</i> , 2011, 10, 144-52.	0.7	12
197	Development of Radiotracers for the Determination of the Beta-Cell Mass In Vivo. <i>Current Pharmaceutical Design</i> , 2010, 16, 1561-1567.	0.9	44
198	Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 226-234.	3.3	43

#	ARTICLE	IF	CITATIONS
199	Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1018-1031.	3.3	113
200	⁶⁸ Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1345-1355.	3.3	124
201	Molecular imaging of angiogenesis with SPECT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 104-113.	3.3	32
202	Carbonic Anhydrase IX in Renal Cell Carcinoma: Implications for Prognosis, Diagnosis, and Therapy. <i>European Urology</i> , 2010, 58, 75-83.	0.9	183
203	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-ethylenetriaminepentaacetic acid F(ab ²) ₂ antibody. <i>Cancer</i> , 2010, 116, 1111-1117.	2.0	20
204	Scanning multiple mice in a small-animal PET scanner: Influence on image quality. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2010, 621, 605-610.	0.7	14
205	Differential susceptibility to lethal endotoxaemia in mice deficient in IL-1 α , IL-1 β or IL-1 receptor type I. <i>Apmis</i> , 2010, 118, 1000-1007.	0.9	24
206	Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small-Animal PET Scanner. <i>Journal of Nuclear Medicine</i> , 2010, 51, 610-617.	2.8	138
207	Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1049-1058.	2.8	245
208	Pretargeted Immuno ⁺ Positron Emission Tomography Imaging of Carcinoembryonic Antigen ⁺ Expressing Tumors with a Bispecific Antibody and a ⁶⁸ Ga- and ¹⁸ F-Labeled Hapten Peptide in Mice with Human Tumor Xenografts. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1019-1027.	1.9	85
209	Imaging of Inflammation by PET, Conventional Scintigraphy, and Other Imaging Techniques. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1937-1949.	2.8	231
210	Pretargeted ¹⁷⁷ Lu Radioimmunotherapy of Carcinoembryonic Antigen ⁺ Expressing Human Colonic Tumors in Mice. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1780-1787.	2.8	49
211	ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1565-1572.	2.8	84
212	Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After ¹⁷⁷ Lu-Labeled Tyr ³ -Octreotate Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1962-1968.	2.8	30
213	SUV: From Silly Useless Value to Smart Uptake Value. <i>Journal of Nuclear Medicine</i> , 2010, 51, 173-175.	2.8	44
214	PET of Hypoxia with ⁸⁹ Zr-Labeled cG250-F(ab ²) ₂ in Head and Neck Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1076-1083.	2.8	98
215	¹¹¹ In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1707-1715.	2.8	47
216	Innovations in Radiotherapy Planning of Head and Neck Cancers: Role of PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 66-76.	2.8	73

#	ARTICLE	IF	CITATIONS
235	Contribution of normalization to image noise for the Siemens Inveon small-animal PET scanner. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2009, 605, 433-435.	0.7	4
236	Radioimmunotherapy Improves Survival of Rats with Microscopic Liver Metastases of Colorectal Origin. Annals of Surgical Oncology, 2009, 16, 2065-2073.	0.7	14
237	In-depth evaluation of the cycloaddition "retro-Diels-Alder reaction for in vivo targeting with [111In]-DTPA-RGD conjugates. Nuclear Medicine and Biology, 2009, 36, 749-757.	0.3	22
238	Animal Models for Liver Metastases of Colorectal Cancer: Research Review of Preclinical Studies in Rodents. Journal of Surgical Research, 2009, 154, 167-176.	0.8	32
239	Versatile Conjugation of Octreotide to Dendrimers by Cycloaddition ("Click" Chemistry to Yield High-Affinity Multivalent Cyclic Peptide Dendrimers. Bioconjugate Chemistry, 2009, 20, 1323-1331.	1.8	34
240	Tumor Accumulation of Radiolabeled Bevacizumab due to Targeting of Cell- and Matrix-Associated VEGF-A Isoforms. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 195-200.	0.7	21
241	Monoclonal Antibody G250 Recognizing Carbonic Anhydrase IX in Renal Cell Carcinoma: Biological and Clinical Studies. , 2009, , 231-247.		1
242	Targeted radionuclide therapy of cancer. , 2009, , 463-496.		5
243	Targeting of a CCK2 receptor splice variant with 111In-labelled cholecystokinin-8 (CCK8) and 111In-labelled minigastrin. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 386-392.	3.3	40
244	Correlation of [18F]FMISO autoradiography and pimonodazole immunohistochemistry in human head and neck carcinoma xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1803-1811.	3.3	85
245	Antibody therapy in renal cell carcinoma. World Journal of Urology, 2008, 26, 141-146.	1.2	5
246	Application of Metal-Free Triazole Formation in the Synthesis of Cyclic RGD-DTPA Conjugates. ChemBioChem, 2008, 9, 1805-1815.	1.3	87
247	Specific imaging of VEGF expression with radiolabeled anti-VEGF monoclonal antibody. International Journal of Cancer, 2008, 122, 2310-2314.	2.3	59
248	The kinetic and biological activity of different loaded rhBMP-2 calcium phosphate cement implants in rats. Journal of Biomedical Materials Research - Part A, 2008, 87A, 780-791.	2.1	80
249	Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. European Journal of Cancer, 2008, 44, 1835-1840.	1.3	59
250	Drosomycin-Like Defensin, a Human Homologue of <i>Drosophila melanogaster</i> Drosomycin with Antifungal Activity. Antimicrobial Agents and Chemotherapy, 2008, 52, 1407-1412.	1.4	32
251	Reducing Renal Uptake of Radiolabeled Peptides Using Albumin Fragments. Journal of Nuclear Medicine, 2008, 49, 1506-1511.	2.8	78
252	Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor. Journal of Nuclear Medicine, 2008, 49, 887-891.	2.8	44

#	ARTICLE	IF	CITATIONS
253	Intratumoral Spatial Distribution of Hypoxia and Angiogenesis Assessed by ¹⁸ F-FAZA and ¹²⁵ I-Gluco-RGD Autoradiography. Journal of Nuclear Medicine, 2008, 49, 1732.1-1732.	2.8	2
254	Multimodality Probes: Amphibian Cars for Molecular Imaging. Journal of Nuclear Medicine, 2008, 49, 1213-1214.	2.8	15
255	Hyperthermia and Fibrinolytic Therapy Do Not Improve the Beneficial Effect of Radioimmunotherapy Following Cytoreductive Surgery in Rats with Peritoneal Carcinomatosis of Colorectal Origin. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 301-309.	0.7	7
256	<i>Review:</i> Intracavitary Radioimmunotherapy to Treat Solid Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 92-107.	0.7	22
257	Use of Radiolabeled Liposomes for Imaging of Infection and Inflammation. , 2008, , 237-251.		0
258	Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. European Heart Journal, 2007, 28, 1085-1091.	1.0	22
259	Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrology Dialysis Transplantation, 2007, 22, 749-755.	0.4	31
260	Development and Application of Peptide-Based Radiopharmaceuticals. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 543-551.	0.9	44
261	Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides. Journal of Nuclear Medicine, 2007, 48, 596-601.	2.8	150
262	Radionuclide Therapy of Cancer with Radiolabeled Antibodies. Anti-Cancer Agents in Medicinal Chemistry, 2007, 7, 335-343.	0.9	20
263	Cancer imaging and therapy with bispecific antibody pretargeting. Update on Cancer Therapeutics, 2007, 2, 19-31.	0.9	82
264	Effects of linker variation on the in vitro and in vivo characteristics of an ¹¹¹ In-labeled RGD peptide. Nuclear Medicine and Biology, 2007, 34, 29-35.	0.3	76
265	PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation. Nuclear Medicine and Biology, 2007, 34, 691-695.	0.3	17
266	Preclinical evaluation of technetium 99m-labeled P1827DS for infection imaging and comparison with technetium 99m IL-8. Nuclear Medicine and Biology, 2007, 34, 925-932.	0.3	5
267	[¹⁸ F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. Hepatology Research, 2007, 37, 127-132.	1.8	6
268	Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Organic and Biomolecular Chemistry, 2007, 5, 935.	1.5	180
269	Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer, 2007, 55, 79-87.	0.9	174
270	Preparation and Evaluation of Glycosylated Arginine- ¹⁴ C-Glycine- ¹⁴ Aspartate (RGD) Derivatives for Integrin Targeting. Bioconjugate Chemistry, 2007, 18, 1847-1854.	1.8	48

#	ARTICLE	IF	CITATIONS
271	Radiolabeled antibodies in renal cell carcinoma. <i>Cancer Imaging</i> , 2007, 7, 179-188.	1.2	23
272	$\alpha_5\beta_1$ Integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. <i>International Journal of Cancer</i> , 2007, 120, 605-610.	2.3	61
273	Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. <i>Journal of Controlled Release</i> , 2007, 117, 186-195.	4.8	61
274	Timing of Adjuvant Radioimmunotherapy after Cytoreductive Surgery in Experimental Peritoneal Carcinomatosis of Colorectal Origin. <i>Annals of Surgical Oncology</i> , 2007, 14, 533-540.	0.7	20
275	Improved targeting of the $\alpha_5\beta_1$ integrin by multimerisation of RGD peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 267-273.	3.3	195
276	Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 413-421.	3.3	16
277	^{99m}Tc -labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. <i>Journal of Nuclear Medicine</i> , 2007, 48, 337-43.	2.8	34
278	Targeting of Biliary Cancer with Radiolabeled Chimeric Monoclonal Antibody CG250. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 263-268.	0.7	7
279	Transforming Growth Factor- β_1 Release from a Porous Electrostatic Spray Deposition- α -Derived Calcium Phosphate Coating. <i>Tissue Engineering</i> , 2006, 12, 2449-2456.	4.9	24
280	Combination Therapy Using Gemcitabine and Radioimmunotherapy in Nude Mice with Small Peritoneal Metastases of Colonic Origin. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006, 21, 506-514.	0.7	12
281	Synthesis and biological evaluation of potent $\alpha_5\beta_1$ -integrin receptor antagonists. <i>Nuclear Medicine and Biology</i> , 2006, 33, 953-961.	0.3	45
282	Imaging hypoxia after oxygenation-modification: Comparing [^{18}F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. <i>Radiotherapy and Oncology</i> , 2006, 80, 157-164.	0.3	72
283	Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning. <i>Journal of the American College of Cardiology</i> , 2006, 48, 700-707.	1.2	65
284	A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. <i>Regulatory Peptides</i> , 2006, 137, 162-167.	1.9	77
285	Development of ^{111}In -labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. <i>Nuclear Medicine and Biology</i> , 2006, 33, 453-458.	0.3	14
286	Nuclear medicine imaging and therapy of neuroendocrine tumours. <i>Cancer Imaging</i> , 2006, 6, S178-S184.	1.2	11
287	Peritoneal Carcinomatosis of Colorectal Origin: Standard of Care. <i>Annals of Surgery</i> , 2006, 244, 633-634.	2.1	0
288	Peritoneal Carcinomatosis of Colorectal Origin. <i>Annals of Surgery</i> , 2006, 243, 212-222.	2.1	442

#	ARTICLE	IF	CITATIONS
289	Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 1266-1272.	3.3	6
290	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 47-55.	2.0	8
291	INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1393-1397.	1.7	203
292	Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. <i>Journal of Nuclear Medicine</i> , 2006, 47, 432-6.	2.8	62
293	Gelatin-based plasma expander effectively reduces renal uptake of ¹¹¹ In-octreotide in mice and rats. <i>Journal of Nuclear Medicine</i> , 2006, 47, 528-33.	2.8	63
294	Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1867-74.	2.8	23
295	Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of ^{99m} Tc labelled epidermal growth factor. <i>Nuclear Medicine Communications</i> , 2005, 26, 147-153.	0.5	15
296	Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. <i>International Journal of Pharmaceutics</i> , 2005, 304, 185-192.	2.6	58
297	Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 52-59.	2.3	48
298	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. <i>Nature Biotechnology</i> , 2005, 23, 1407-1413.	9.4	791
299	Discriminating infection from sterile inflammation: can radiolabelled antibiotics solve the problem?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 151-152.	3.3	23
300	Comparison of IgG and F(ab ²) fragments of bispecific anti-RCCA ⁺ —anti-DTIn-1 antibody for pretargeting purposes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 1089-1095.	3.3	9
301	Antibody-guided radiation therapy of cancer. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 539-567.	2.7	51
302	Lack of Efficacy of Two Consecutive Treatments of Radioimmunotherapy With ¹³¹ I-cG250 in Patients With Metastasized Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 6540-6548.	0.8	80
303	Biodistribution and Imaging of FDG in Rats with LS174T Carcinoma Xenografts and Focal Escherichia coli Infection. <i>Cancer Biotherapy and Radiopharmaceutics</i> , 2005, 20, 310-315.	0.7	9
304	In vivo Molecular Prediction of Carbonic Anhydrase IX-G250MN Expression on Immunotherapy Outcome in Renal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 8886-8886.	3.2	4
305	Radioimmunotherapy with [¹³¹ I]cG250 in Patients with Metastasized Renal Cell Cancer: Dosimetric Analysis and Immunologic Response. <i>Clinical Cancer Research</i> , 2005, 11, 7178s-7186s.	3.2	40
306	Annexin A5 Scintigraphy of Forearm as a Novel In Vivo Model of Skeletal Muscle Preconditioning in Humans. <i>Circulation</i> , 2005, 111, 173-178.	1.6	47

#	ARTICLE	IF	CITATIONS
307	Pretargeting of Carcinoembryonic Antigen-Expressing Tumors with a Biologically Produced Bispecific Anticarcinoembryonic Antigen- ¹²⁵ I-Anti-Indium- ¹¹¹ In-Labeled Diethylenetriaminepentaacetic Acid Antibody. <i>Clinical Cancer Research</i> , 2005, 11, 7130s-7136s.	3.2	15
308	Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. <i>Radiotherapy and Oncology</i> , 2005, 76, 194-199.	0.3	56
309	Synthesis of Leukotriene B4 Antagonists Labeled with In-111 or Tc-99m to Image Infectious and Inflammatory Foci. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 6442-6453.	2.9	8
310	Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. <i>Journal of Nuclear Medicine</i> , 2005, 46, 495-501.	2.8	31
311	Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1016-22.	2.8	17
312	Imaging of infection and inflammation with an improved ^{99m} Tc-labeled LTB4 antagonist. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1546-51.	2.8	10
313	Improved Tumor Targeting of Radiolabeled RGD Peptides Using Rapid Dose Fractionation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 399-404.	0.7	36
314	Tracers to Monitor the Response to Chemotherapy: In Vitro Screening of Four Radiopharmaceuticals. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 457-465.	0.7	2
315	Two Technetium-99m-Labeled Cholecystokinin-8 (CCK8) Peptides for Scintigraphic Imaging of CCK Receptors. <i>Bioconjugate Chemistry</i> , 2004, 15, 561-568.	1.8	43
316	PET Radioimmunoscinigraphy of Renal Cell Cancer Using ⁸⁹ Zr-Labeled cG250 Monoclonal Antibody in Nude Rats. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 155-163.	0.7	62
317	Pharmacokinetics and Tumor Targeting of ¹³¹ I-Labeled F(ab') ₂ Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 466-477.	0.7	13
318	^{99m} Tc-Labeled Interleukin-8 for Scintigraphic Detection of Pulmonary Infections. <i>Chest</i> , 2004, 126, 1954-1961.	0.4	17
319	Pharmacokinetics and Tumor Targeting of ¹³¹ I-Labeled F(ab') ₂ Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 466-477.	0.7	22
320	Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with ¹³¹ I, ⁹⁰ Y, ¹⁷⁷ Lu, or ¹⁸⁶ Re. <i>Journal of Nuclear Medicine</i> , 2004, 45, 327-37.	2.8	99
321	Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (^{99m} Tc)-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1217-23.	2.8	6
322	Biodistribution and therapeutic efficacy of (¹²⁵ I)-, (¹⁸⁶ Re)-, (⁸⁸ / ⁹⁰ Y)-, or (¹⁷⁷ Lu)-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1224-32.	2.8	53
323	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. <i>International Journal of Cancer</i> , 2003, 106, 965-972.	2.3	34
324	Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. <i>Arthritis and Rheumatism</i> , 2003, 48, 2059-2066.	6.7	281

#	ARTICLE	IF	CITATIONS
325	Analysis of dendritic cell trafficking using EGFP-transgenic mice. <i>Immunology Letters</i> , 2003, 89, 17-24.	1.1	43
326	Nuclear medicine imaging to predict response to radiotherapy: a review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 5-15.	0.4	82
327	Monoclonal antibody-based therapy for renal cell carcinoma. <i>Urologic Clinics of North America</i> , 2003, 30, 623-631.	0.8	24
328	Long-Lived Positron Emitters Zirconium-89 and Iodine-124 for Scouting of Therapeutic Radioimmunoconjugates with PET. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 655-661.	0.7	111
329	Interferons Can Upregulate the Expression of the Tumor Associated Antigen G250-MN/CA IX, a Potential Target for (Radio)Immunotherapy of Renal Cell Carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 539-547.	0.7	20
330	Biodistribution of ¹³¹ I-, ¹⁸⁶ Re-, ¹⁷⁷ Lu-, and ⁸⁸ Y-Labeled hLL2 (Epratuzumab) in Nude Mice with CD22-Positive Lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 525-533.	0.7	25
331	Peptides and Monoclonal Antibodies in Oncology: An Introduction. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003, 18, 591-592.	0.7	1
332	Radiolabeling of Liposomes for Scintigraphic Imaging. <i>Methods in Enzymology</i> , 2003, 373, 234-248.	0.4	17
333	Title is missing!. <i>Clinical Nuclear Medicine</i> , 2003, 28, 480-484.	0.7	1
334	Evaluation of Tc-99m Labeled Glycoprotein IIb/IIIa Receptor Antagonist DMP444 SPECT in Patients with Infective Endocarditis. <i>Clinical Nuclear Medicine</i> , 2003, 28, 480-484.	0.7	11
335	Monoclonal Antibody Therapy of Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 199-212.	0.2	6
336	Molecular Imaging of Infection and Inflammation. , 2003, , 233-251.		0
337	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. <i>Cancer Research</i> , 2003, 63, 12-7.	0.4	659
338	Pretargeted radioimmunotherapy of cancer: progress step by step. <i>Journal of Nuclear Medicine</i> , 2003, 44, 400-11.	2.8	155
339	A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1087-91.	2.8	17
340	Kinetics of ^{99m} Tc-labeled interleukin-8 in experimental inflammation and infection. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1502-9.	2.8	17
341	Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (¹³¹ I) or (¹¹¹ In): an inpatient comparison. <i>Clinical Cancer Research</i> , 2003, 9, 3953S-60S.	3.2	41
342	Final results of a phase I radioimmunotherapy trial using (¹⁸⁶ Re)-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2003, 9, 3995S-4002S.	3.2	25

#	ARTICLE	IF	CITATIONS
343	Quantitative ⁸⁹ Zr immuno-PET for in vivo scouting of ⁹⁰ Y-labeled monoclonal antibodies in xenograft-bearing nude mice. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1663-70.	2.8	72
344	Dosimetric analysis of radioimmunotherapy with ¹⁸⁶ Re-labeled bivatuzumab in patients with head and neck cancer. <i>Journal of Nuclear Medicine</i> , 2003, 44, 1690-9.	2.8	24
345	Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor Targeting. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 641-646.	0.7	153
346	Phenotypical and Functional Characterization of Clinical Grade Dendritic Cells. <i>Journal of Immunotherapy</i> , 2002, 25, 429-438.	1.2	140
347	Effects of Coligand Variation on the In Vivo Characteristics of Tc-99m-Labeled Interleukin-8 in Detection of Infection. <i>Bioconjugate Chemistry</i> , 2002, 13, 370-377.	1.8	37
348	Scintigraphic imaging using ^{99m} Tc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. <i>Nuclear Medicine and Biology</i> , 2002, 29, 177-184.	0.3	18
349	Re: Selective in vitro labeling of white blood cells using ^{99m} Tc-labeled liposomes. <i>Nuclear Medicine and Biology</i> , 2002, 29, 623.	0.3	1
350	Fluorinated amino acids for tumour imaging with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 681-690.	3.3	153
351	Fluorinated amino acids for tumour imaging with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 834-834.	3.3	37
352	Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. <i>Cancer Research</i> , 2002, 62, 6146-51.	0.4	258
353	Imaging infection/inflammation in the new millennium. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 241-252.	2.2	156
354	Radiopharmaceuticals to image infection and inflammation. <i>Seminars in Nuclear Medicine</i> , 2001, 31, 286-295.	2.5	76
355	The effect of molecular weight on nonspecific accumulation of ^{99m} Tc-labeled proteins in inflammatory foci. <i>Nuclear Medicine and Biology</i> , 2001, 28, 401-408.	0.3	20
356	Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. <i>Blood</i> , 2001, 98, 1802-1811.	0.6	383
357	Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1725-1735.	2.2	27
358	Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1447-1449.	3.3	40
359	Lethal <i>Escherichia coli</i> and <i>Salmonella typhimurium</i> endotoxemia is mediated through different pathways. <i>European Journal of Immunology</i> , 2001, 31, 2529-2538.	1.6	42
360	Microscopic localization of PEG-liposomes in a rat model of focal infection. <i>Journal of Controlled Release</i> , 2001, 75, 347-355.	4.8	47

#	ARTICLE	IF	CITATIONS
361	Lethal Escherichia coli and Salmonella typhimurium endotoxemia is mediated through different pathways. European Journal of Immunology, 2001, 31, 2529.	1.6	1
362	In Vivo Applications of PEG Liposomes: Unexpected Observations. Critical Reviews in Therapeutic Drug Carrier Systems, 2001, 18, 16.	1.2	61
363	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharmaceutical Research, 2000, 17, 600-606.	1.7	44
364	Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 392-399.	3.3	23
365	Lyophilization of Tc-99m-Hynic Labeled Peg-Liposomes. Journal of Liposome Research, 2000, 10, 117-129.	1.5	9
366	Pretargeted Radioimmunotherapy of Non-Hodgkin's Lymphoma: Best of Both Worlds?. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 1-5.	0.7	2
367	Radio-labeled receptor-binding peptides: A new class of radiopharmaceuticals. Seminars in Nuclear Medicine, 2000, 30, 195-208.	2.5	61
368	Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. Nuclear Medicine and Biology, 2000, 27, 599-604.	0.3	33
369	Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. Journal of Drug Targeting, 2000, 8, 225-233.	2.1	60
370	Liposomes for scintigraphic detection of infection and inflammation. Advanced Drug Delivery Reviews, 1999, 37, 225-235.	6.6	75
371	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1419, 325-334.	1.4	101
372	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	2.1	30
373	Two-step radio-immunotargeting of renal-cell carcinoma xenografts in nude mice with anti-renal-cell-carcinoma X anti-DTPA bispecific monoclonal antibodies. , 1998, 75, 74-80.		22
374	Imaging of infection in rabbits with radioiodinated interleukin-1 ($\hat{1}\pm$ and $\hat{1}^2$), its receptor antagonist and a chemotactic peptide: a comparative study. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 347-352.	3.3	38
375	Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 535-546.	3.3	36
376	BACTERIAL LIPOPOLYSACCHARIDE BINDS AND STIMULATES CYTOKINE-PRODUCING CELLS BEFORE NEUTRALIZATION BY ENDOGENOUS LIPOPROTEINS CAN OCCUR. Cytokine, 1998, 10, 766-772.	1.4	58
377	Sterically Stabilized Liposomes to Image Infection and Inflammation. , 1998, , 229-240.		1
378	The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer, 1997, 80, 2390-2397.	2.0	32

#	ARTICLE	IF	CITATIONS
379	Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 1531-1535.	2.2	25
380	Macrophage targeting in experimental arthritis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 727-727.	2.2	0
381	Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 414-421.	2.2	33
382	The uptake mechanisms of inflammation-and infection-localizing agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 459-465.	2.2	36
383	Role of fibroblasts in the regulation of proinflammatory interleukin IL-1, IL-6 and IL-8 levels induced by keratinocyte-derived IL-1. <i>Archives of Dermatological Research</i> , 1996, 288, 391-398.	1.1	92
384	Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 212-219.	2.2	29
385	Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 1249-1255.	2.2	46
386	Specific antibody uptake in tuberculosis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1993, 20, 568-569.	2.2	4
387	Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 127-134.	2.0	19
388	Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotypic antibody in tumor-bearing nude mice. <i>International Journal of Cancer</i> , 1992, 51, 266-273.	2.3	27
389	The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). <i>International Journal of Oncology</i> , 1992, 32, 1145-1157.	1.4	40
390	Tissue distribution of ^{99m} Tc, ¹¹¹ In and ¹²³ I-OV-TL 3 Fab [€] in ovarian carcinoma bearing nude mice. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1991, 18, 77-83.	0.3	4
391	Comparative Immunohistochemical Study of Four Monoclonal Antibodies Directed Against Ovarian Carcinoma-Associated Antigens. <i>International Journal of Gynecological Pathology</i> , 1991, 10, 15-25.	0.9	48
392	Novel antigens characteristic of neuroendocrine malignancies. <i>Cancer</i> , 1991, 67, 619-633.	2.0	24
393	The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: An autoradiographic study. <i>Cancer Immunology, Immunotherapy</i> , 1991, 33, 351-358.	2.0	50
394	Sensitive Determination of Circulating Anodic Antigen in Schistosoma mansoni Infected Individuals by an Enzyme-Linked Immunosorbent Assay using Monoclonal Antibodies. <i>American Journal of Tropical Medicine and Hygiene</i> , 1989, 40, 268-272.	0.6	160